Clinical trials sponsored by Genfleet Therapeutics (Shanghai) Inc.

Phase breakdown

Conditions studied

Recruiting trials led by Genfleet Therapeutics (Shanghai) Inc.

• A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
  NCT07259590 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
  NCT07668752 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
  NCT07262567 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Genfleet Therapeutics (Shanghai) Inc. recruiting for?

Genfleet Therapeutics (Shanghai) Inc. is the lead sponsor of 3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.